Life Sciences

  • January 02, 2026

    Patent Policy To Watch In 2026

    After a year of significant shifts in U.S. Patent and Trademark Office policy on patent reviews and patent eligibility, attorneys will be closely following how the changes play out in 2026, along with proposals for further moves, and whether Congress decides to weigh in on patents.

  • January 02, 2026

    California Cases To Watch In 2026

    Legal experts following California courts in 2026 are tracking high-stakes personal injury, antitrust and copyright battles against giants in the social media, artificial intelligence and entertainment industries, as well as wide-ranging legal disputes arising from Los Angeles wildfires and high-profile appeals pending before the California Supreme Court.

  • January 02, 2026

    North Carolina Cases To Watch In 2026

    In the new year, North Carolina state and federal courts are set to consider the intricacies of class action certification at the behest of thousands of fast-food workers and whether Chinese company TikTok Inc. is deliberately designing the app to addict children.

  • January 02, 2026

    New Jersey Cases To Watch In 2026

    In the coming year, New Jersey litigators will be watching for the outcome of an appeal in a constitutional challenge to school segregation and an employment discrimination case brought by a former Johnson & Johnson attorney. 

  • January 02, 2026

    What To Watch In Massachusetts Courts In 2026

    Massachusetts attorneys have their eye on Trump administration policy challenges, state ballot question disputes and False Claims Act enforcement shifts as the calendar turns to 2026.

  • January 02, 2026

    SnapChat, Pork And Big Prosecutions: Trials To Watch In 2026

    The coming year is set to bring high-profile trials, including in the criminal case against SCOTUSblog co-founder Tom Goldstein, as well as bellwether trials in multidistrict litigation concerning social media's effects on mental health and allegations of price-fixing in the generic-drug industry.

  • January 02, 2026

    Pennsylvania Cases To Watch In 2026

    As winter's chill rings in the new year, several high-profile cases are set to heat up Pennsylvania's dockets in 2026, including disciplinary charges against a judge associated with rapper Meek Mill, a pending appeals decision on the lawfulness of semiautomatic rifles, and Philadelphia's quest to hold pharmacy benefit managers accountable for the opioid epidemic.

  • January 02, 2026

    Patent Cases To Watch In 2026

    The U.S. Supreme Court is considering whether to weigh in on generic-drug skinny labels, while the Federal Circuit is examining an effort by the U.S. Patent and Trademark Office to shield decisions from review. Here's a look at those cases and others that attorneys will be tracking in 2026.

  • January 02, 2026

    The High-Stakes Healthcare AI Battles To Watch In 2026

    Courts across the country are set to hear a wave of litigation in the coming year that will begin to draw the legal boundaries around artificial intelligence in healthcare and the life sciences. Law360 spoke with legal experts about the high-stakes AI litigation set to unfold in 2026.

  • January 01, 2026

    4 High Court Cases To Watch This Spring

    The U.S. Supreme Court justices will return from the winter holidays to tackle several constitutional disputes that range from who is entitled to birthright citizenship to whether transgender individuals are entitled to heightened levels of protection from discrimination. 

  • January 01, 2026

    Blue Slip Fight Looms Over Trump's 2026 Judicial Outlook

    In 2025, President Donald Trump put 20 district and six circuit judges on the federal bench. In the year ahead, a fight over home state senators' ability to block district court picks could make it more difficult for him to match that record.

  • January 01, 2026

    BigLaw Leaders Tackle Growth, AI, Remote Work In New Year

    Rapid business growth, cultural changes caused by remote work and generative AI are creating challenges and opportunities for law firm leaders going into the New Year. Here, seven top firm leaders share what’s running through their minds as they lie awake at night.

  • December 24, 2025

    Sanofi Buys Hepatitis Vaccine Maker Dynavax For $2.2B

    French pharmaceutical giant Sanofi SA said Wednesday that it will buy Dynavax Technologies, a U.S. vaccine developer, for $2.2 billion in a recommended cash deal to expand its adult immunization products.

  • December 23, 2025

    Top Illinois Decisions Of 2025

    State and federal courts have handed down rulings in Illinois cases this year that made clear plaintiffs must allege concrete injury for common law standing, narrowed the scope of the federal anti-kickback statute and laid out a new standard for certifying collective actions.

  • December 23, 2025

    3 Federal Circuit Clashes To Watch In January

    The Federal Circuit is set to hear several intellectual property cases in January, including one over a nine-figure patent judgment against cybersecurity company Gen Digital tied to a contempt finding against a major law firm that represented it, and another over the tech industry's long-running crusade against patent review denials based on related litigation.

  • December 23, 2025

    Philly Joins MDL Against Drug Cos., PBMs Over Insulin Prices

    Philadelphia on Tuesday sued drug manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with several pharmacy benefit managers, joining multidistrict litigation in New Jersey federal court accusing the companies of illegally inflating the price of insulin.

  • December 23, 2025

    Justices Urged To Spurn SG's Call To Tackle 'Skinny Labels'

    Amarin Pharma Inc. on Tuesday urged the U.S. Supreme Court to reject the U.S. solicitor general's call to hear a patent case involving generic drug "skinny labels," saying the dispute over the company's heart drug Vascepa deals with factual issues not suitable for high court review.

  • December 23, 2025

    AdaptHealth To Pay Investors $35M To End Inflated-Sales Suit

    Medical device provider AdaptHealth Corp. has agreed to pay $35 million to settle a lawsuit accusing it of deceiving shareholders about its revenue projections as it "routinely engaged in improper and unethical tactics to inflate sales numbers." 

  • December 23, 2025

    Dem Sens. Blast Idea Of Charging Value-Based Patent Fees

    A group of Democratic U.S. senators has asked Commerce Secretary Howard Lutnick not to move forward with a proposed overhaul of the U.S. patent fee system that reportedly would implement fees based on a patent's value, saying such changes would create a "prohibitive bar to innovation for start-ups and other small-to-mid-size businesses."

  • December 23, 2025

    Squires Will Review If Hydrafacial's ITC Win Should End IPR

    U.S. Patent and Trademark Office Director John Squires has paused the Patent Trial and Appeal Board's review of a Hydrafacial LLC skin treatment patent to consider the effect of a related U.S. International Trade Commission decision.

  • December 23, 2025

    Federal Agencies Urge 9th Circ. To Lift Layoff Freeze

    The U.S. government urged the Ninth Circuit to stay a court order barring agencies from laying off workers through next month under the shutdown deal, saying the court intruded on federal labor panels' territory and the funding resolution didn't bar layoffs agencies had in the works.

  • December 23, 2025

    Blue Cross Seeks McDonald Hopkins' Fraud Warning Docs

    Advice that McDonald Hopkins LLC gave a Florida hospital manager about potential exposure to criminal prosecution for healthcare fraud is neither privileged nor work product, and so should be handed over to a Blue Cross health insurer being sued for malicious prosecution in Georgia federal court, the insurer said.

  • December 23, 2025

    Top New Jersey Cases Of 2025

    New Jersey courts saw some history-making litigation come to a close over the course of 2025, including the largest environmental settlement ever achieved by a single state and the first clergy abuse trial verdict since the statute of limitations on child sexual abuse claims was extended. Another notable development was the state's federal bench exercising a rarely used authority to reject President Donald Trump's pick for interim U.S. attorney.

  • December 23, 2025

    Sanofi Eczema Drug Linked To Lymphoma, Suit Says

    Drug manufacturers Regeneron Pharmaceuticals and Sanofi were hit with a lawsuit Monday from a Georgia woman alleging the companies have covered up a "strong and consistent causal relationship" between their drug Dupixent and a form of non-Hodgkins lymphoma.

  • December 23, 2025

    Baker Botts Hires 2 New DC Partners For Enviro, IP Team

    Baker Botts LLP has hired two new partners in its intellectual property and environmental safety and incident response groups, who will both be based in the firm's Washington, D.C., office, Baker Botts said in recent announcements.

Expert Analysis

  • Agentic AI Puts A New Twist On Attorney Ethics Obligations

    Author Photo

    As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.

  • Using Reissue Applications To Strategically Improve Patents

    Author Photo

    Though reissue applications are an often-overlooked consideration in today's patent environment, they can offer powerful tools for correcting errors, strengthening patent protection, or adapting to evolving business and legal landscapes, says Curtis Powell at Wolf Greenfield.

  • FDA Transparency Plans Raise Investor Disclosure Red Flags

    Author Photo

    The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.

  • Series

    Being A Professional Wrestler Makes Me A Better Lawyer

    Author Photo

    Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.

  • Patent Claim Lessons From Fed. Circ.'s Teva Decision

    Author Photo

    The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley.

  • Series

    Law School's Missed Lessons: Adapting To The Age Of AI

    Author Photo

    Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.

  • Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning

    Author Photo

    A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.

  • DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech

    Author Photo

    The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.

  • Future-Proof Patent Law By Starting Talent Pipelines Early

    Author Photo

    Law firms struggling with a narrow talent pipeline in the intellectual property space should consider beginning their recruitment strategies for potential candidates as early as high school, and raise awareness for career opportunities that do not require a law degree, says Christine Hollis at Marshall Gerstein.

  • Demystifying The Civil Procedure Rules Amendment Process

    Author Photo

    Every year, an advisory committee receives dozens of proposals to amend the Federal Rules of Civil Procedure, most of which are never adopted — but a few pointers can help maximize the likelihood that an amendment will be adopted, says Josh Gardner at DLA Piper.

  • How USPTO Examiner Memo Informs Software Patent Drafting

    Author Photo

    A memorandum recently released by the U.S. Patent and Trademark Office provides useful clues as to how the USPTO and examining corps will evaluate claims in software-implemented inventions for subject matter eligibility going forward, says Michael Lew at Squire Patton.

  • How 2nd Circ. Cannabis Ruling Upends NY Licensing

    Author Photo

    A recent Second Circuit decision in Variscite NY Four v. New York, holding that New York's extra-priority cannabis licensing preference for applicants with in-state marijuana convictions violates the dormant commerce clause, underscores that state-legal cannabis markets remain subject to the same constitutional constraints as other economic markets, say attorneys at Harris Beach.

  • Parenting Skills That Can Help Lawyers Thrive Professionally

    Author Photo

    As kids head back to school, the time is ripe for lawyers who are parents to consider how they can incorporate their parenting skills to build a deep, meaningful and sustainable legal practice, say attorneys at Alston & Bird.

  • Enablement Standard Insights From Fed. Circ. Agilent Ruling

    Author Photo

    The Federal Circuit's recent enablement standard decision in Agilent v. Synthego underscores three critical takeaways for patent practitioners, including reaffirmation that the enablement inquiry under Section 102 of the Patent Act is distinct from the inquiry under Section 112, say attorneys at MoFo.

  • Series

    Teaching Trial Advocacy Makes Us Better Lawyers

    Author Photo

    Teaching trial advocacy skills to other lawyers makes us better litigators because it makes us question our default methods, connect to young attorneys with new perspectives and focus on the needs of the real people at the heart of every trial, say Reuben Guttman, Veronica Finkelstein and Joleen Youngers.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.